Patents by Inventor Gregory Hinkle

Gregory Hinkle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE
    Publication number: 20130035371
    Abstract: This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene.
    Type: Application
    Filed: August 7, 2012
    Publication date: February 7, 2013
    Inventors: Kevin Fitzgerald, Gregory Hinkle, Akin Akinc, Stuart Milstein
  • Compositions and Methods for Inhibiting Expression of XBP-1 Gene
    Publication number: 20130023580
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 24, 2013
    Inventors: Kevin Fitzgerald, Gregory Hinkle
  • Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
    Publication number: 20130012572
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting Glycogen Synthase Kinase-3 (GSK-3), and methods of using the dsRNA to inhibit expression of GSK-3.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Inventors: Dinah Wen-Yee Sah, Gregory Hinkle
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20130012571
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: NOVARTIS AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • Compositions and methods for inhibiting expression of XBP-1 gene
    Patent number: 8344126
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: January 1, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Gregory Hinkle
  • Organic compositions to treat Beta-ENaC-related diseases
    Patent number: 8344129
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • Organic compositions to treat beta-ENaC-related diseases
    Patent number: 8344127
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Sprague
  • Organic compositions to treat Beta-ENaC-related diseases
    Patent number: 8344130
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • Organic compositions to treat beta-ENaC-related diseases
    Patent number: 8344131
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 8324368
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: December 4, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Organic compositions to treat HSF1-related diseases
    Patent number: 8293718
    Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: October 23, 2012
    Assignee: Novartis AG
    Inventors: Gregory Hinkle, Satyanarayana Kuchimanchi, Stuart Milstein, Markus Warmuth, Wenlai Zhou, Ping Zhu, Tracy S. Zimmermann
  • Lipid formulated dsRNA targeting the PCSK9 gene
    Patent number: 8273869
    Abstract: This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: September 25, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Gregory Hinkle, Akin Akinc, Stuart Milstein
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN
    Publication number: 20120225927
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.
    Type: Application
    Filed: March 1, 2012
    Publication date: September 6, 2012
    Inventors: Dinah Wen-Yee Sah, Gregory Hinkle, Rene Alvarez, Stuart Milstein, Qingmin Chen
  • ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES
    Publication number: 20120129915
    Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Application
    Filed: February 1, 2012
    Publication date: May 24, 2012
    Applicant: NOVARTIS AG
    Inventors: Gregory HINKLE, Satyanarayana KUCHIMANCHI, Stuart MILSTEIN, Markus WARMUTH, Wenlai ZHOU, Ping ZHU, Tracy S. ZIMMERMANN
  • ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES
    Publication number: 20120129914
    Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Application
    Filed: February 1, 2012
    Publication date: May 24, 2012
    Applicant: NOVARTIS AG
    Inventors: Gregory HINKLE, Satyanarayana KUCHIMANCHI, Stuart MILSTEIN, Markus WARMUTH, Wenlai ZHOU, Ping ZHU, Tracy S. ZIMMERMANN
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20120122960
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 17, 2012
    Applicant: NOVARTIS AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20120115934
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 10, 2012
    Applicant: NOVARTIS AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20120115933
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 10, 2012
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • Compositions and methods for inhibiting expression of transthyretin
    Patent number: 8168775
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: May 1, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Gregory Hinkle, Rene Alvarez, Stuart Milstein, Qingmin Chen
  • Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
    Publication number: 20120041051
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting MIDI interacting G12-like protein (MIG 12) gene, and methods of using the dsRNA to inhibit expression of MIG 12.
    Type: Application
    Filed: February 25, 2010
    Publication date: February 16, 2012
    Inventors: Kevin Fitzgerald, Gregory Hinkle